Shared on08 Aug 25Fair value Increased 7.65%
Upward revisions to Niagen Bioscience's price target reflect positive clinical trial results confirming both safety and significant efficacy of its NAD+ supplementation, increased market confidence, and ongoing product and sales momentum, resulting in a higher consensus analyst price target rising from $14.90 to $15.84. Analyst Commentary Positive clinical study results published in a peer-reviewed journal demonstrated that Niagen Bioscience’s NAD+ supplementation is safe for patients with Werner syndrome and achieved a ~140% increase in blood NAD+ levels, along with improvements in liver, kidney, and arterial health markers.
Shared on30 Jul 25Fair value Increased 71%
Niagen Bioscience's consensus price target was significantly raised from $8.72 to $14.90, reflecting strong analyst confidence driven by successful clinical trial results, robust TruNiagen sales growth, and encouraging pipeline progress. Analyst Commentary Positive clinical trial results published in a peer-reviewed journal demonstrated the safety and significant NAD+ level increase (~140%) from supplementation in patients with Werner syndrome, along with improvements in key clinical markers such as liver, kidney, and arterial health.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on12 Mar 25Fair value Increased 8.46%
AnalystConsensusTarget has decreased profit margin from 14.8% to 13.2% and increased future PE multiple from 32.8x to 41.3x.